Hepatocellular carcinoma - Latest research and news - Nature
网页2024年9月11日 · Resistance to immune checkpoint blockade (ICB) is a challenge in hepatocellular carcinoma therapy. Here, the authors show that targeting PRMT3 markedly improves the anticancer efficacy of ICB...
What’s new in treating hepatocellular carcinoma, the most …
网页2023年4月14日 · Hepatocellular carcinoma, the most common type of liver cancer, has historically been difficult to treat since most people diagnosed with the disease have existing liver disease. But thanks to new research, there’s good news for hepatocellular carcinoma treatment, says Ahmed Kaseb, M.D.
Hepatocellular Carcinoma in 2021: An Exhaustive Update
网页2021年11月5日 · The current review is aimed at providing exhaustive updates on the etiology, molecular biology, biomarker diagnosis, imaging, and recommended treatment options in patients with HCC. Keywords: tace, bclc, ablation, liver transplantation, chronic hepatitis, cirrhosis, portal hypertension, liver cancer. Go to:
Update on the Diagnosis and Treatment of Hepatocellular Carcinoma
网页Hepatocellular carcinoma (HCC) is the fourth-leading cause of cancer-related mortality worldwide and the fastest-rising cause of cancer-related death in the United States. Given the strong association between tumor stage and prognosis, HCC surveillance is recommended in high-risk patients, including patients with cirrhosis from any etiology.
Immunotherapy at all stages of hepatocellular carcinoma
网页2024年2月26日 · A flurry of emerging treatment options is transforming the therapeutic landscape of hepatocellular carcinoma; two new studies highlight the complexities and gaps in knowledge, but also hint at...
Hepatocellular carcinoma | Nature Reviews Disease Primers
网页2021年1月21日 · Hepatocellular carcinoma (HCC) is the most common form of liver cancer and accounts for ~90% of cases. Hepatitis B virus (HBV) infection is the most prominent risk factor for HCC...
Global, regional, and national burden of primary liver cancer …
网页2021年12月20日 · Globally, hepatocellular carcinoma accounts for 80% of all cases of primary liver cancer, intrahepatic cholangiocarcinoma for 15% of all cases, and other subtypes for the remaining 5%.
Hepatocellular Carcinoma | New England Journal of Medicine
网页2019年4月10日 · Hepatocellular carcinomas are complex ecosystems incorporating nontumor cells, mainly immune-related cells. The success of immune checkpoint inhibition in solid tumors underscores...
Drug Development in Hepatocellular Carcinoma ... - ASCO Daily News
网页2023年1月5日 · The past decade has seen substantial progress in drug development in hepatocellular carcinoma (HCC), with the standard of care shifting from sorafenib to atezolizumab plus bevacizumab during an explosion of immunotherapeutic research.
Systemic Therapy for Advanced Hepatocellular Carcinoma …
网页2024年3月19日 · Dr. John Gordan discusses the newest evidence-based guideline update from ASCO on systemic therapy for advanced hepatocellular carcinoma (HCC). He shares the updated recommendations for first-, second-, and third-line therapy for patients with Child-Pugh Class A liver disease, guidance for patients with Child-Pugh Class B …
跳至内容